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Abstract The acceptability and use of the diaphragm and
lubricant gel were assessed as part of a large randomized
controlled trial to determine the effectiveness of the
methods in women’s HIV acquisition. 2,452 intervention-
arm women were enrolled at ﬁve Southern African clinics
and followed quarterly for 12–24 months. Acceptability
and use data were collected by face-to-face interviews at
Month 3 and Exit. Participants were ‘‘very comfortable’’
with the physical mechanics of diaphragm use throughout
the trial, and approval of the gel consistency, quantity and
the applicator was high. At Exit, consistent disclosure of
use (AOR 1.97, 95% CI: 1.10–3.55); an overall high dia-
phragm rating (AOR 1.84, 95% CI: 1.45–2.34) and per-
ception of partner approval (AOR 1.75, 95% CI:
1.35–2.26) were the most signiﬁcant acceptability factors
independently associated with consistent use. Despite
being female-initiated, disclosure of use to male partners
and his perceived approval of the products were factors
signiﬁcantly associated with their consistent use.
Keywords Diaphragm  Lubricant gel  HIV prevention 
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Background
Globally the HIV epidemic continues to progress, with
Southern Africa at the epicentre of the pandemic [1].
Within this region, women are more likely to be infected
than men. Much of the exacerbated risk women face is
attributed to their increased biological, socio-economic and
cultural vulnerability to HIV infection [2–4]. In an attempt
to address this gender imbalance, there are several ongoing
investigations of female-initiated HIV prevention technol-
ogies, such as vaginal microbicides, cervical barriers, and
combinations thereof. Female-initiated methods would
offer women greater control over use, including undis-
closed use, which may be important in relationships where
women are unable to negotiate male condoms.
The Methods for Improving Reproductive Heath in
Africa (MIRA) study was a phase III randomized trial
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DOI 10.1007/s10461-009-9609-zexamining the effectiveness of the diaphragm, a non-con-
traceptive lubricant gel (Replens
) and condoms, com-
pared to condoms alone in preventing HIV acquisition in
Southern African women. As recently published, there was
no additional protective beneﬁt against HIV infection or
cervical STIs, when the diaphragm and gel were provided
in addition to condoms and a comprehensive HIV pre-
vention package [5, 6]. A secondary objective of the trial
was to assess the acceptability of the diaphragm and gel
throughout the study period. As others have discussed,
‘‘acceptability’’ is a multi-dimensional concept which
incorporates different meanings in different settings, and at
different stages of a product lifecycle [7]. In MIRA, we
focused on the clinical testing stage, and the broad domain
of ‘‘acceptability’’ included an evaluation of user per-
spectives about the physical characteristics of product use
(including comfort, ease of use, effect on sexual pleasure),
as well as discrete use, female-initiation and partner sup-
port for use. This is the ﬁrst large randomized study to
examine the acceptability and use of the diaphragm and gel
as a potential HIV/STI prevention method during 12–
24 months of study participation.
Previous research on the diaphragm as a contraceptive
hasshownthedevicetobeacceptableinseveraldeveloping-
country settings where historically it had not been widely
available [8–10]. In a recent US contraceptive trial of the
diaphragm,used with acontraceptive microbicide candidate
or placebo, two-thirds of women reported strongly or
somewhat liking the method [11]. In research settings where
the diaphragm has been investigated as a potential HIV/STI
prevention method, high user-acceptability has also been
reported among diverse target groups, including reproduc-
tive health clinic attendees, sex-workers and ‘‘healthy’’
community-recruited women [12, 13]. Several studies in the
developing world have also looked at acceptability of
potential microbicidal gels, exploring issues regarding
insertion,consistency,quantity,sexualpleasureandwetness
among women and their male partners. Although the
majority have reported the gels are acceptable, most of the
studies have been small, short in duration, or have examined
hypothetical acceptability [8, 9, 14–24].
Acceptability is presumed to be an important component
of use, however, their relationship is inconsistent in the
literature. A study in Zimbabwe preceding this trial
reported an association between women’s diaphragm
acceptability and consistent use, while another recent trial,
also in Zimbabwe, reported that partner acceptability was
independently associated with consistent diaphragm use,
although women’s own diaphragm acceptability was not
[21, 25]. Finally, a study of young women in the US that
measured use under more ‘‘real life’’ conditions, accept-
ability of barrier methods was reported to be an unreliable
predictor of future use [26].
This paper presents overall long-term acceptability of
the diaphragm and gel, as well as acceptability of several
speciﬁc attributes of their use as a potential HIV preven-
tion method. We also examined whether these factors
differed by time point, and which speciﬁc attributes of
product acceptability were independently associated with
consistent product use. The MIRA trial produced ﬁndings
that would not warrant scale-up of the diaphragm and
lubricant gel for HIV/STI prevention, but our results may
have been different if use of the products had been higher
[5]. Cervical barriers and microbicide gels are still under
investigation for this indication, and acceptability and use
results from MIRA are thus important to consider in this
context.
Methods
Study Design and Participants
The MIRA trial enrolled 5,045 women HIV-negative, non-
pregnant women at three sites in South Africa (2 clinics
adjacent to Durban, 1 in Soweto) and Zimbabwe (2 clinics
adjacent to Harare) between September 2003 and Decem-
ber 2006. Six participants were discontinued on the same
date of randomization for not meeting inclusion criteria, or
were later identiﬁed as under 18 and were excluded from
the analysis dataset, resulting in an analytic sample of
5,039. Women were randomized in a 1:1 ratio to one of two
study groups and received an Ortho All-Flex diaphragm,
Replens
 lubricant gel and male condoms (intervention
group) or male condoms alone (control group). Participants
were counseled to insert the diaphragm with one-applica-
tor-full (2.5 g) in the dome at any time before sex; to insert
an additional applicator-full of gel in the vagina at least 1 h
prior to sex, to retain the products for at least 6 h post
coitus, and to use all of their assigned study products for
every act of sex. All women received a comprehensive
package of voluntary counseling and testing for HIV,
treatment for curable STIs, and intensive risk reduction
counseling with health education. Participants were
scheduled to attend a two-week post-enrollment visit and
quarterly follow-up assessments that continued for 12–
24 months, depending on the calendar date of their
enrollment. Trial participants were recruited from family
planning, well-baby and general health clinics, as well as
through community outreach, local media and word-of-
mouth (further detailed in: Padian et al. [5]). The MIRA
study is registered with ClinicalTrials.gov (number
NCT00121459).
This analysis focuses on the 2,521 women randomized
to the intervention group. Acceptability of the intervention
group products was assessed using an interviewer-
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123administered questionnaire delivered at the ﬁrst quarterly
follow-up visit (Month 3) and at the participant’s last visit
(Exit). To understand if general or speciﬁc aspects of
product acceptability changed with duration of use, we
compared acceptability responses from Month 3 and Exit.
The majority (2,485, 98.6%) of women had acceptability
data from at least one time point. Eighteen participants
were excluded from the analytic sample because they
reported non-use of the diaphragm since the start of the
study, and ﬁfteen were excluded because they were late for
their Month 3 Visit, and did not have an Exit visit. Of the
2,452 women remaining, 2,208 (88%), women had a
Month 3 acceptability interview, 2,317 (92%) had an Exit
acceptability interview, and 2,073 (85%) had data for both
Month 3 and Exit. Because of the study’s staggered follow-
up period, exit visits ranged in quarterly intervals from
Month 12 to Month 24 (median Month 21).Thus for the
exit visit data, 12% of responses were at Month 12, 16%
each at Months 15 and 18, 14% at Month 21, and 42% at
Month 24 (Fig. 1).
Measures
Product Acceptability
We measured participant’s general rating of the diaphragm
and gel with the questions, ‘‘How would you rate the dia-
phragm overall?’’ and, ‘‘How would you rate the gel
overall?’’ (strongly like vs. like/dislike/strongly dislike).
We also focused on several speciﬁc aspects of acceptability
that were relevant to use of the diaphragm and gel, and
pertinent to use of female-initiated methods in general.
These included women’s comfort inserting, removing, and
wearing a device intravaginally (very comfortable vs.
somewhat/not at all comfortable); comfort with the quan-
tity and consistency of the gel (just right vs. not just right)
and the insertion of an intravaginal applicator of gel (very
comfortable vs. somewhat/not at all comfortable); effects
on sexual pleasure and frequency (increased vs. no effect/
decreased); use of the products continuously; use for dual
protection (pregnancy/disease/both) and comparisons of
the ease and preference for diaphragm vs. male condoms
(prefer diaphragm vs. prefer condom/the same). We also
assessed partner knowledge (he knew every time vs.
\every time); and acceptance of product use (he strongly
likes vs. all other responses) as well as decision-making
regarding use (decided jointly/he decided/she decided).
Consistent Product Use
The outcome variable of consistent use of the combina-
tion product (diaphragm and gel) was derived from
responses to two questions in the Acceptability ques-
tionnaire where exposure variables were also assessed.
First we asked whether the diaphragm was ever used
since the start of the study (yes/no). Those who answered
afﬁrmatively were then asked, ‘‘If there have been times
during the study when you did not use the diaphragm and
gel during vaginal sex, what was the most important
reason?’’ From among nine responses, those who chose:
‘‘Not applicable, you used them for every sex act’’ were
categorized as ‘‘consistent users’’ and all other responses
as ‘‘inconsistent users.’’ Use of this ‘‘opt-in’’ technique
which assumes participants had not been fully compliant
with product use, has been shown to decrease social
desirability bias in responses to sensitive behaviors [27].
Finally, the use data were collected in the same manner as
the acceptability exposure variables, making associations
easier to assess.
Potential Confounders
For the multivariate models evaluating the association
between product acceptability and use, we considered a set
  2 Excluded from 
sample: (1 underage 
and 1 discontinued on 
date of randomization)
  36 with no Acceptability 
data
￿  18 did not use 
diaphragm or 
gel during study 
￿ 15  no 
acceptability 
data at Month 3 
or Exit 
2523
Intervention
group 
5045 randomized to 
study 
2522 Control 
group 
2485 with at least one 
Acceptability interview 
2452 
2208 Month 3 
Acceptability 
interviews 
2317 Exit Acceptability 
interviews 
￿  277 (12%) Month 12 
￿  379 (16%) Month 15 
￿  360 (16%) Month 18 
￿  325 (14%) Month 21 
￿  976 (42%) Month 24 
Fig. 1 Proﬁle of MIRA acceptability and use analysis
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123of baseline socio-demographic (e.g. age, education, marital
status), clinical (i.e. baseline STI) and risk perception (e.g.
impression of partner’s ﬁdelity) variables that could be
associated with both acceptability and adherence and thus
act as potential confounders. Those baseline characteristics
that were associated in bivariate analysis at the P B 0.20
level, as well as age and site (irrespective of association
level) were then included in multiple logistic regression
models with the outcome of interest. Those potential con-
founders that remained signiﬁcant at the P B 0.20 level
were included in the ﬁnal multivariate models.
Statistical Analysis
Measures of product acceptability were summarized for the
two study time points (Month 3 and Exit) using descriptive
frequencies. We ruled out multicollinearity in acceptability
factors at each time by evaluating variance inﬂation factors
and Spearman’s rank correlations. To examine the associ-
ation between the speciﬁc aspects of acceptability and use,
we constructed two multivariate logistic regression models,
one for each time point of interest. Acceptability factors
signiﬁcant in bivariate analyses at the P B 0.10 level, and
all potential confounders previously identiﬁed as signiﬁ-
cant in multivariate analysis (described above) were
retained in the ﬁnal models. Because of concerns that
highly correlated variables were obstructing relationships
with the outcome, we used a backwards selection proce-
dure to determine the variables independently predictive of
use. All data were analyzed using SAS, version 9.1.
Results
Table 1 displays the baseline characteristics of the MIRA
intervention group sample. Over three-quarters (78.1%) of
the participants were under 35; 59.4% were married and
67.9% report living together with their primary male
partner. The majority reported two or more live births
(58.1%). Less than half (44.8%) were high-school edu-
cated. Less than a quarter (23.2%) were formally
employed; although many more (56.9%) report earning
income in the past year. Fewer than half (42.9%) had
running tap water inside of their homes. Approximately
two-thirds of participants were using hormonal or longer-
term contraceptives. Only one woman had previously used
a diaphragm. Thirty percent of women reported that they
knew or suspected their partner had another sexual partner
in the past 3 months, and a further forty percent ‘‘didn’t
know’’. The subset of participants included in this analysis
(92%) did not differ signiﬁcantly on any variables exam-
ined for the entire intervention group (data not shown).
General Acceptability of Diaphragm and Gel
Overall, we found high reported acceptability of the dia-
phragm and gel at both the Month 3 and Exit visits
(Table 2). Seventy-one percent of intervention group par-
ticipants reported ‘‘strongly liking’’ the diaphragm at both
time points, and the proportion of participants ‘‘strongly
liking’’ the gel increased from 51.9% at Month 3 to 61.6%
by Exit. At the end of the trial women were asked whether
they would recommend the diaphragm and gel to a friend if
they were shown to be effective in preventing HIV/STIs,
and almost all (96.6%) responded afﬁrmatively.
Physical Characteristics of Products and Their Use
At Month 3, the majority of participants reported feeling
very comfortable inserting (88.9%), removing (90.1%),
having the diaphragm in situ (88.2%), and retaining the
diaphragm intravaginally for 6 h post-coitus (82.5%).
Attitudes towards these components of use remained rela-
tively constant or increased slightly between Month 3 and
Exit (Table 2). Many felt that the quantity and consistency
of the gel (83.6 and 89.2%, respectively) were ‘‘just right’’
at Month 3, and reported being very comfortable inserting
the gel applicator (78.7%). Favorable attitudes towards
these gel factors increased by Exit. A smaller proportion of
women reported strongly liking the guideline to insert the
gel within an hour of sex (41.8% at Month 3, 50.4% at
Exit).
When asked to compare diaphragms to condoms, more
women started out reporting that they preferred diaphragms
to condoms (57.2%), and found them easier to use (55.1%).
However, by exit, more women found them equivalent, or
favored condoms.
Effect on Sex
An increased effect of the diaphragm and gel on sexual
pleasure and frequency was minimal. Approximately one-
third (33.1%) of participants at Month 3 reported that the
diaphragm and gel increased their sexual pleasure, and
21.4% said it increased their sexual frequency. Both of
these proportions declined by Exit to 23.5 and 16.6%,
respectively.
Female-Initiation and Use Patterns
An important attribute of the diaphragm and gel is that it is
female-initiated. Just under two-thirds of our study par-
ticipants reported that they were the primary decision
maker in the use of the products at both time points (59.7
and 63.2%, respectively: Table 2). While almost half of the
women agreed at Month 3 that it was ‘‘very important’’ that
632 AIDS Behav (2010) 14:629–638
123they could use the diaphragm and gel without their partners
knowing, this proportion declined to 40.7% at Exit, and
throughout the study period, the majority (range 70.5–
71.8%) of participants disclosed use of the diaphragm to
their partner(s) every time they had sex. The majority of
women reported the perception that their partner felt use of
the diaphragm was a good idea (71.0% at Month 3, 68.9%
at Exit).
Participants were offered free hormonal contraceptives
through the trial. Nonetheless, over half (53% at both time
points) reported using the diaphragm for both disease and
pregnancy prevention (although not necessarily their sole
contraceptive method).
Association Between Product Acceptability and Use
At the Month 3 visit, 66.4% of women reported using the
diaphragm and gel every time they had sex since the start
of the study. This proportion decreased to 51.6% at Exit.
Several factors related to product acceptability were
independently associated with consistent use of the device
at both time points. At Month 3, women who ‘‘strongly
Table 1 Baseline
characteristics of MIRA
intervention group participants,
for the acceptability analysis
sample (n = 2,452)
a Long term/user independent
methods include tubal ligation,
vasectomy, injectables, IUD,
implants such as Jadelle &
Norplant
b Pill methods includes
combined oral contraceptive
and progestin only pills
c Barrier methods include male
or female condoms and
diaphragm
d Includes Chlamydia (CT),
Gonnorhea (GC),
Trichomoniasis (TV) and
Syphilis (TP)
e At least one indicator (vs.
none) of: Any exchange of sex
for money, food or shelter; sex
under the inﬂuence or 2 or more
sex partners in the past 3
months; ever had anal sex; and/
or ever used a needle for
injectable drug use
f At least one indicator (vs.
none) of: Ever had a known
HIV-positive partner, know or
suspect partner has multiple
partners, had sex under the
inﬂuence in the past 3 months
and/or partner away from home
[1 month
n %
Socio-demographic
Age 24 years old or younger 969 39.5
25–34 years old 945 38.6
35 years old or older 537 21.9
Education Less than high school education 1,352 55.2
Marital status Married 1,457 59.4
Earned income in past year Yes 1,392 56.9
Employed Employed 569 23.2
Source of water Tap water inside premises 1,050 42.9
Tap water outside premises 956 39.1
Well water 365 14.9
River/stream/rain water and other 77 3.2
Site (main language used in trial) Harare, Zimbabwe (Shona) 1,230 50.2
Durban, South Africa (Zulu) 732 29.9
Johannesburg, South Africa (Zulu, Sotho) 490 19.9
Parity 0 births 217 8.9
1 birth 811 33.1
2? births 1,424 58.1
Current contraceptive use at
screening
Long term/user independent
a 736 30.0
Pill
b 900 36.7
Barrier
c 507 20.7
Other/none 309 12.6
Ever used diaphragm No 2,451 99.9
Sexual & risk behavior
Lifetime # of sexual partners,
mean (range)
2.2 (1–20)
Age at ﬁrst sex, mean (range) 18 (10–29)
Number of sexual partners in the
past 3 months
0 152 6.2
1 2,094 85.6
2 or more 201 8.2
Know or suspect partner had other
sexual partners in past 3 months
Yes 734 30.0
No 723 29.6
Don’t know 990 40.5
Baseline STI
d Yes 377 15.4
Baseline HSV-2 Yes 1,402 57.2
Coital frequency 3 times per week or less 1,586 64.7
High behavior risk
e Yes 687 28.1
High partner risk
f Yes 1,679 68.6
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123liked’’ the diaphragm (AOR 1.69, 95% CI: 1.34–2.12), or
reported that their partners reactions were favorable (AOR
1.59, 95% CI: 1.19–2.13), and those who made a joint
decision with their partner to use the products (AOR: 1.53,
95% CI: 1.02–2.28) were more likely to consistently use
the diaphragm and gel (Table 3). Women who felt the
consistency of the gel was ‘‘just right’’ (AOR 1.54, 95% CI:
1.12–2.12), or that the diaphragm and gel increased sexual
pleasure (1.36, 95% CI: 1.08–1.69), and those that pre-
ferred diaphragms to condoms (AOR 1.36, 95% CI: 1.11–
1.67), were also more likely to consistently use (Table 3).
By Exit, several different characteristics of the dia-
phragm and gel emerged as independently associated with
consistent use. The strongest association with consistent
use occurred among those reporting that their partner knew
about diaphragm use at every sex act (AOR: 1.97, 95% CI:
1.10–3.55). A somewhat complementary ﬁnding related to
female-initiation and disclosure was that women who felt
that it was ‘‘very important’’ to be able to use the products
without the partner’s knowledge were less likely to con-
sistently use them (AOR: 0.73, 95% CI: 0.60–0.89).
Women’s own strong liking of the diaphragm, and the
perception that her partner’s reactions were favorable
remained independently associated with use (AOR 1.84,
95% CI: 1.45–2.34 and AOR 1.75, 95% CI: 1.35–2.26,
respectively). Joint decision-making regarding diaphragm
use also remained independently associated with use (AOR
1.52, 95% CI: 1.02–2.25). Those who were ‘‘very com-
fortable’’ waiting 6 h before removing the diaphragm were
more likely to consistently use the diaphragm and gel
Table 2 Diaphragm and gel acceptability: overall and speciﬁc attributes at Month 3 and Exit
Month 3 (n = 2,208)
a Exit (n = 2,317)
a
n % n %
Overall acceptability
Diaphragm
Strongly likes 1,583 71.7 1,646 71.1
Likes 577 26.1 574 24.8
Dislikes/strongly dislikes 48 2.2 95 4.1
Gel
Strongly likes 1,138 51.9 1,417 61.6
Likes 903 41.2 731 31.8
Dislikes/strongly dislikes 153 7.0 151 6.6
Would recommend to a friend if proven effective NA NA 2,263 96.6
Physical characteristics of products and use
Very comfortable inserting diaphragm 1,962 88.9 2,150 92.8
Very comfortable removing diaphragm 1,988 90.1 2,170 93.7
Very comfortable waiting 6 h after sex before removing diaphragm 1,821 82.5 1,906 82.3
Very comfortable having diaphragm in situ 1,946 88.2 2,103 90.8
Very comfortable inserting gel applicator 1,732 78.7 1,901 82.6
Amount of gel is just right 1,839 83.6 2,074 89.9
Consistency of gel is just right 1,961 89.2 2,183 94.7
Strongly like inserting gel before sex 918 41.8 1,162 50.4
Prefers diaphragm to condoms 1,262 57.2 943 40.7
Thinks diaphragms easier to use than condoms 1,215 55.1 880 38.0
Effect on sex
Diaphragm and gel increases sexual pleasure 730 33.1 544 23.5
Diaphragm and gel increases sexual frequency 472 21.4 384 16.6
Female-initiation and use patterns
Very important you can use diaphragm without partner knowing 1,099 49.8 944 40.7
Partner knew diaphragm in use every time 1,584 71.8 1,633 70.5
Partner thinks diaphragm is a good idea 1,555 71.0 1,579 68.9
She decides when to use diaphragm 1,309 59.7 1,457 63.2
Uses diaphragm for disease and pregnancy prevention 1,177 53.4 1,240 53.6
a Responses and proportions do not always correspond to full sample because of missing information
634 AIDS Behav (2010) 14:629–638
123(AOR 1.45, 95% CI: 1.12–1.88). Finally, while women
who reported ‘‘strongly liking’’ condoms were more likely
to consistently use the diaphragm and gel (AOR 1.31, 95%
CI: 1.04–1.66), those who found diaphragms easier to use
than condoms were also more likely to be consistent
product users (AOR 1.23, 95% CI: 1.01–1.50).
Discussion
This study highlights several important ﬁndings that are
relevant to the acceptability and introduction of novel
female-initiated methods of HIV prevention. Diaphragms
and gels for either contraceptive or disease prevention
purposes were hardly known, available, or distributed prior
to this study in these Southern African communities.
Despite this fact, the majority of the study population
found them easy and comfortable to insert, wear and
remove over the entire study period, suggesting that
women are receptive and capable of easily adopting new
intravaginal technologies. The overall proportion of
women strongly liking the diaphragm remained high (71%)
over the 2 year study period, and improved over time for
the gel. That said, fewer than 60% reported consistent use
of the diaphragm throughout the course of the study, and
while more than half the women preferred and found dia-
phragms easier to use than condoms in the early period, by
Exit, more women found diaphragms and condoms equally
preferable and equally easy to use. Since the acceptability
of many speciﬁc attributes of the diaphragm and gel
increased at Exit, the latter ﬁnding may be a result of
successful condom counseling and condom use, rather than
a decreased enthusiasm for the diaphragm and gel.
In this study, women’s report of strongly liking the
diaphragm overall was associated with its consistent use in
both the early and late time periods. This ﬁnding supports
the association between acceptability and use, and cor-
roborates ﬁndings reported from two smaller and shorter
duration cervical barrier studies in Zimbabwe [21, 25].
Insofar as acceptability is linked to product use and ulti-
mately effectiveness, and keeping into consideration that
an important component of acceptability may be duration
of use, there is a continued need for formative and ongoing
evaluation of product acceptability in the pre-clinical,
clinical testing and in roll-out/marketing stages of the
development of other new female-initiated HIV prevention
methods. Further it is important to consider that consistent
use may not be associated with acceptability of each
individual attribute of a given product, for example one
may not like the feel or required negotiation of male
condoms, but may use them because of their protective
effect.
Several measures of male partner attitudes, support and
communication between couples were also identiﬁed in
Table 3 Multivariate logistic regression model for the association between acceptability and consistent use of the diaphragm and gel at month 3
and exit*
Month 3 (n = 2,145)** Exit (n = 2,247)***
AOR 95% CI AOR 95% CI
Physical characteristics of products and use
Very comfortable waiting 6 h after sex before removing diaphragm NA 1.45 1.12–1.88
Prefers diaphragm to condoms 1.36 1.11–1.67 NA
Thinks diaphragms are easier to use than condoms NA 1.23 1.01–1.50
Strongly likes diaphragm overall 1.69 1.34–2.12 1.84 1.45–2.34
Diaphragm and gel increases sexual pleasure 1.36 1.08–1.69 NA
Consistency of gel is just right 1.54 1.12–2.12 NA
Strongly likes male condoms NA 1.31 1.04–1.66
Female-initiation and use patterns
Thinks it very important diaphragm can be used without partner’s knowledge NA 0.73 0.60–0.89
Partner knew diaphragm in use every time NS 1.97 1.10–3.55
Partner’s general reactions to using diaphragm good (vs. neutral or bad) 1.59 1.19–2.13 1.75 1.35–2.26
Both partners have ﬁnal word on diaphragm use (vs. HE does alone) 1.53 1.02–2.28 NS
Both partners have ﬁnal word on diaphragm use (vs. SHE does alone) NS 1.52 1.02–2.25
* Only acceptability factors signiﬁcant at the p\ 0.05 level presented. NA = variable not included in ﬁnal model; NS = variable included in
ﬁnal model but not signiﬁcant
** Also controlling for: site, age, source of water in the home, education, knowledge of other partners
*** Also controlling for: site, age, source of water in the home, education, contraceptive use, parity, number of sexual partners in the last 3
months
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123this study to be associated with consistent use. This
underscores several opinion articles and evidence from
other studies that even with female-initiated HIV preven-
tion methods, the role of the male partner is critical for
women’s uptake and continuous use [28]. Here, women’s
perceptions that their male partner supported use of the
study products was associated with consistent use at both
time periods, as has been reported in other studies [21, 25].
Three indicators of couples communication measured in
this study suggest important relationships with use: joint
decision-making and full disclosure of product use were
associated with consistent use, while valuing the impor-
tance of clandestine use was associated with inconsistent
use. Thus, efforts to gain male partner support for study
product use may improve adherence in similar trials of
female-initiated methods. This might be accomplished
through early involvement of male partners in trial
enrollment procedures and product counseling. More
research into the identiﬁcation of innovative strategies for
including male partners while still ensuring women’s
autonomy is needed, and female trial participants may help
inform this research.
One strategy for enlisting greater male partner support
and potentially improving adherence to female-initiated
methods might be to emphasize ways in which study
products might enhance sexual pleasure. At Month 3,
women who felt the diaphragm and gel made sex more
pleasurable were more likely to be consistent users,
although by the Exit Visit, this was no longer indepen-
dently associated with use. The beneﬁt of eroticizing dis-
ease prevention methods, or highlighting their potentially
pleasurable attributes has been discussed by others, but
perhaps still needs more emphasis in individual or couples-
based counseling [7, 29, 30].
While the relationship and contextual dynamics
regarding the use of intravaginal devices and gels are
essential components of women’s acceptability, as many
have argued [28, 31, 32], it is also important to continue to
measure basic attitudes towards the physical properties of
investigational products, even well past their develop-
mental stage in phase III clinical trials. As described above,
women in this study were very comfortable using the
diaphragm and gel, and in particular, those who were ‘‘very
comfortable’’ wearing the diaphragm for 6 h post-coitus
were more likely to consistently use the products. This
ﬁnding has implications for use of other female-initiated
methods in coitally-dependent and continuous use regi-
mens. A study in Madagascar has reported that continuous
use of the diaphragm was acceptable in a sex worker
population [16], and a safety and acceptability study
comparing continuous use vs. pre-coital use of a dia-
phragm-like device (Duet
) for 14-days in a general pop-
ulation will further address these issues [33]. In the MIRA
trial, participants were advised to use the diaphragm, gel
and condoms for every act of sex. Nonetheless, substitution
of products (i.e. use of the diaphragm and gel instead of
condoms or vice versa) was a concern, which we explored
in separate quantitative and qualitative analyses. In the
former, 83.1% of women reported use of the diaphragm
instead of condoms at least some of the time [34]. In this
study, at Exit, both women who reported an overall ‘‘strong
liking’’ of the diaphragm and gel and those reporting the
same for male condoms were more likely to be consistent
diaphragm and gel users, suggesting that a strong liking of
male condoms does not necessarily preclude consistent
diaphragm and gel use.
There are several potential limitations to this study.
First, the measures of acceptability and adherence relied on
self-report of participants’ attitudes and behaviors that may
have been subject to social desirability and recall bias. This
limitation is true of most studies of this nature, and
underscores the need for better measures (including bio-
markers) and techniques for eliciting honest reporting.
Participants who were lost-to-follow-up did not receive an
Exit acceptability assessment and may have missed a
Month 3 assessment; and these participants may have been
less likely to like the study products. We chose an outcome
measure for consistent product use from the acceptability
form that may have been less reliable than the Computer-
based self-administered (ACASI) variables, however, we
conﬁrmed that the overall rate of consistent use reported by
FTFI was congruent and virtually identical with our
ACASI data which collected consistent use in the past
3 months [5, 35].
In summary, we found high acceptability of a combi-
nation method as a potential HIV/STIs preventative in the
MIRA trial. The overall rating of the diaphragm remained
consistently high and that of gel increased with time.
However, attitudes towards several speciﬁc attributes of the
products changed with time, and in both directions. It is
important for trials of female-initiated methods, particu-
larly those with longer follow-up periods, to conduct
multiple assessments of product acceptability, as some
attitudes may change with sustained use. It is also impor-
tant to measure several different aspects of investigational
products (physical attributes, effect on sex, partner’s sup-
port, etc.) to understand the relative importance of each
within the context of a given population, and over time, and
this will be particularly important as products transition
from clinical studies to the general public. Despite high
levels of reported acceptability, the proportion of women
that reported consistent use was only moderate (*50% at
Exit). As a recent modeling paper highlighted, these sub-
optimal levels of adherence, as we observed in the MIRA
trial, would dramatically decrease the measured efﬁcacy of
an intervention, thus eliminating the power of the study to
636 AIDS Behav (2010) 14:629–638
123detect an effect, if true biological efﬁcacy existed [36].
This underscores the importance of understanding factors
that promote or discourage consistent use. Here, several
acceptability factors were independently associated with
consistent use, most notably, partner approval/liking of the
study products and open disclosure and joint decision-
making around use. Thus, our results suggest that even
though the diaphragm and gel are female-initiated, the role
of the male partner is critical for product acceptance and
use among women in stable partnerships participating in a
clinical trial. Future studies of this nature might consider
strategies to more actively engage male partners as a way
to optimize product adherence. Nonetheless, women’s
control over use of these products remains important: if
female-initiated methods are proven effective and become
widely available, women- and particularly select sub-pop-
ulations such as unmarried women, those with casual or
multiple partners or sex workers- might need or want to use
them more autonomously than was observed in this study.
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